3.89

5.43% -0.25

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $3.89, with a volume of 999.12K. It is down -5.43% in the last 24 hours and up +26.29% over the past month. Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Previous Close:

$4.14

Open:

$4.15

24h Volume:

999.12K

Relative Volume:

0.86

Market Cap:

$259.45M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-4.1828

EPS:

-0.93

Net Cash Flow:

$-31.47M

1W Performance:

-8.53%

1M Performance:

+26.29%

6M Performance:

+14.81%

1Y Performance:

+65.54%

1-Day Range:

$3.84

$4.1866

1-Week Range:

$3.73

$4.52

52-Week Range:

$2.01

$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1162)

Industry

Biotechnology (651)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	3.90	285.40M	488.00K	-41.44M	-31.47M	-0.93
VRTX Vertex Pharmaceuticals Inc	467.67	122.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	563.06	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	327.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	592.49	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	292.01	31.91B	3.81B	-644.79M	-669.77M	-6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Jun-24-25	Initiated	Jefferies	Hold
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Jul 24, 2025

What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional

Jul 24, 2025

Is Cardiff Oncology Inc. a good long term investmentRapidly expanding wealth - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional

Jul 23, 2025

Jul 22, 2025

What drives Cardiff Oncology Inc. stock priceFast-track wealth growth - jammulinksnews.com

Jul 22, 2025

What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser

Jul 22, 2025

Jul 18, 2025

Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha

Jul 18, 2025

Jul 15, 2025

How Cardiff Oncology Inc. stock performs during market volatilityHigh Return Setup Scanner - Newser

Jul 15, 2025

Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser

Jul 15, 2025

Jul 11, 2025

Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail

Jul 11, 2025

Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World

Jul 11, 2025

Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World

Jul 11, 2025

Jul 09, 2025